THE BRIGHAM AND WOMEN'S HOSPITAL, INC.

The DAPA ACT HF-TIMI 68 trial failed to show significant improvement in cardiovascular death or worsening heart failure when starting dapagliflozin during acute heart failure hospitalization, with 10.9% of treated patients versus 12.7% of placebo patients experiencing events at 60 days.

Monthly olezarsen injections reduced triglyceride levels by approximately 60% at 6 months compared to placebo in patients with moderate hypertriglyceridemia and elevated cardiovascular risk.

Researchers from NTU and MIT developed COMET, an AI model that predicts optimal lipid nanoparticle formulations for RNA medicine delivery, published in Nature Nanotechnology.

The FDA has approved a new indication for Biktarvy to treat HIV patients with treatment history who are not virologically suppressed and are restarting antiretroviral therapy.

Mass General Brigham researchers analyzed data from nearly 50,000 type 2 diabetes patients and found glipizide associated with a 13% increase in cardiovascular risk compared to DPP-4 inhibitors.

Chromophobe renal cell carcinoma (ChRCC) demonstrates an immune-cold tumor microenvironment with significantly reduced CD8+ T-cell infiltration compared to clear cell RCC, explaining poor immunotherapy responses.

PP405 demonstrated significant hair density improvements in men with advanced hair loss, with 31% showing greater than 20% increase at 8 weeks compared to 0% in placebo group.

Humacyte's acellular tissue engineered vessel (ATEV) demonstrated superior functional patency compared to standard arteriovenous fistulas in high-risk hemodialysis patients with end-stage kidney disease.

Dr. Elizabeth Mittendorf, the 2026-2027 ASCO President-Elect, will focus on advancing multidisciplinary collaboration, broadening clinical trial access, and strengthening oncology workforce support during her presidency.

Catalyst Pharmaceuticals appointed Dr. William T. Andrews as Chief Medical Officer, succeeding retiring Dr. Gary Ingenito after his successful 10-year tenure with the company.